Who is sponsoring NCT05140187?

NCT05140187 is sponsored by Chinese PLA General Hospital.

What drugs are being tested in NCT05140187?

Interventions in NCT05140187: CMV-TCR-T cells.

What condition does NCT05140187 study?

NCT05140187 studies CMV Infection After Allogenic HSCT.

Is NCT05140187 still recruiting?

NCT05140187 is currently status unknown. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT05140187

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CMV-TCR-T Cells for CMV Infection After Allogenic HSCT

Status unknown Phase 1 Last updated 29 March 2023

What this trial tests

Phase 1 trial testing CMV-TCR-T cells in CMV Infection After Allogenic HSCT in 12 participants. Status unknown.

Timeline

15 October 2021

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Chinese PLA General Hospital
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	15 October 2021
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

CMV-TCR-T cells — full drug profile →

Conditions studied

CMV Infection After Allogenic HSCT — all drugs for CMV Infection After Allogenic HSCT →

Sponsor

Chinese PLA General Hospital

Who can join

Adults 1 to 60, any sex, with CMV Infection After Allogenic HSCT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, single arm, open-label, phase I study to determine the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating CMV virus infection after allogenic HSCT.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells.
Li J, Xiao Z, Wang D, Jia L, et al · · 2023 · cited 52× · PMID 37649123 · DOI 10.1186/s12943-023-01844-5
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation.
Ma C, Chen P, Du J, Wang L, et al · · 2024 · cited 17× · PMID 38184303 · DOI 10.1136/jitc-2023-007735
TCR-T cell therapy for solid tumors: challenges and emerging solutions.
He W, Cui K, Farooq MA, Huang N, et al · · 2025 · cited 10× · PMID 40129944 · DOI 10.3389/fphar.2025.1493346
Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies.
Zhang W, Zeng M, Li Y, Yu L. · · 2024 · cited 2× · PMID 39075601 · DOI 10.1186/s40364-024-00617-6
CMV-specific T-cell receptor-engineered T-cell therapy as first-line treatment for CMV reactivation after haploidentical hematopoietic stem cell transplantation: a phase 2 trial.
Tang J, Wen Y, Yang T, Liu Q, et al · · 2026 · PMID 42220477 · DOI 10.3389/fimmu.2026.1820399

Verify or expand the search:

Other trials of CMV-TCR-T cells

Trials testing the same drug.

NCT04153279 — CMV-TCR-T Cells for CM Virus Infection After HSCT · Phase 1 · completed

Other Chinese PLA General Hospital trials

Trials by the same sponsor.

NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05140187 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05140187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing